MedSurg and Neurotechnology
Revenue Exposure
MedSurg and Neurotechnology generated $15,647M (~62%) of 2025 total net sales across Instruments, Endoscopy, Medical, Vascular and Neuro Cranial lines.
Relevance 95·Dependency 62·Confidence 99
Source evidence
“$15,647
$13,518
$12,163”
United States
Revenue Exposure
US accounted for $19,006M of $25,116M 2025 net sales (~76%), growing 12.2% as reported.
Relevance 90·Dependency 76·Confidence 97
Source evidence
“United States
$19,006
$16,943
$15,257
12.2%”
Orthopaedics
Revenue Exposure
Orthopaedics generated $9,469M (~38%) of 2025 total net sales across Knees, Hips, Trauma and Extremities, Spinal Implants and Other.
Relevance 90·Dependency 38·Confidence 99
Source evidence
“$9,469
$9,077
$8,335”
Sole-source suppliers and sterilization service providers
Supplier Dependency
Sole-source procurement means supplier failure could halt manufacturing of one or more products; past electronic component shortage caused lost sales.
Relevance 85·Dependency 80·Confidence 95
Source evidence
“If sole-source suppliers or service providers are unable or unwilling to deliver these materials or services as a result of financial difficulties, business disruptions, acquisition by a third party, natural disasters, embargoes, tariffs or otherwise, we may not be able to manufacture or have available one or more products”
Tariffs
Geopolitical Exposure
US tariffs and retaliatory measures could disrupt supply chain, component availability, and cause customers to reduce or delay orders.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“Inflation, high interest rates, interest rate volatility or proposed or enacted tariffs may also cause our customers to reduce or delay orders for our products and services.”
EU Medical Device Regulation (MDR)
Regulatory Exposure
MDR compliance is a significant cost with a staggered phase-in through December 2028; non-compliance risks fines, seizures, recalls, and suspension of manufacturing or sales.
Relevance 80·Dependency 75·Confidence 95
Source evidence
“We incur significant costs to comply with regulations, including the MDR.”
Euro is among the currencies in which ~24% of net sales are denominated; USD strength/weakness drives translation effects.
Relevance 75·Dependency 65·Confidence 96
Source evidence
“approximately 24% of our net sales are denominated in foreign currencies, including the Australian Dollar, British Pound, Canadian Dollar, Euro and Japanese Yen.”
Artificial intelligence / robotics adoption by competitors
Competitive Exposure
Competitors and new entrants may integrate robotics, AI and machine learning more quickly, threatening demand for existing products.
Relevance 75·Dependency 60·Confidence 92
Source evidence
“Our existing competitors and new market entrants may respond more quickly to or integrate new or emerging technologies such as robotics, artificial intelligence (AI) and machine learning in their product offerings”
FDA medical device regulation
Regulatory Exposure
Most products regulated by FDA under the Medical Device Amendments of 1976; many new products require 510(k) notification or pre-market approval with clinical testing.
Relevance 75·Dependency 60·Confidence 92
Source evidence
“many
of our new products fall into FDA classifications that require notification submitted as a 510(k) and review by the FDA before
we begin marketing them.”
Rejuvenate/ABGII hip stems, LFIT V40 Femoral Heads, Wright legacy hips
Legal Exposure
Ongoing product liability lawsuits over hip implant products create uncertain outcomes and potential significant legal expenses.
Relevance 75·Dependency 50·Confidence 95
Source evidence
“We are currently defendants in a number of product liability matters, including those relating to our Rejuvenate and ABGII Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads and the product liability lawsuits and claims relating to Wright Medical Group N.V. (Wright) legacy hip products”
Mako SmartRobotics
Revenue Exposure
Mako robotics is a key Orthopaedics growth platform: >45 countries, >2M cumulative robotic procedures; Mako 4 launched 2025 with first-to-market robotic revision hip application.
Relevance 75·Dependency 45·Confidence 90
Source evidence
“Mako Total Hip with Advanced Primary and Revision represents Stryker's first-to-market, robotically enabled revision hip arthroplasty procedure.”
Stryker Corporation
Competitive Exposure
Spine reporting unit impairment driven by decreased future product demand due to competitive environment.
Relevance 70·Dependency 50·Confidence 90
Source evidence
“The impairment charge for the Spine reporting unit was driven by a decrease in future product demand due to the competitive environment”
Medtronic plc
Competitive Exposure
Medtronic named as a leading global competitor in Instruments and Vascular/Neuro Cranial product lines.
Relevance 70·Dependency 40·Confidence 95
Source evidence
“the other four being Medtronic, Johnson &
Johnson MedTech, Terumo Corporation and Penumbra, Inc.”
Zimmer Biomet Holdings, Inc.
Competitive Exposure
Zimmer Biomet named as a leading global competitor in Instruments and in joint replacement, trauma and extremities products and robotics.
Relevance 70·Dependency 40·Confidence 95
Source evidence
“We are one of four leading global competitors for joint replacement and trauma and extremities products and robotics; the other three being Zimmer, Johnson & Johnson MedTech and Smith & Nephew.”
Vascular (Neurovascular + Inari)
Revenue Exposure
Vascular sales grew 50.6% as reported in 2025 to $1,968M, driven by the Inari Medical acquisition (venous thromboembolism products).
Relevance 70·Dependency 40·Confidence 92
Source evidence
“Vascular
1,968
1,307
1,226
50.6
50.0
107.5”
Vascular (minimally invasive stroke and venous thromboembolism products) grew rapidly to $1,968M in 2025 from $1,307M in 2024, with US sales more than doubling.
Relevance 70·Dependency 8·Confidence 90
Source evidence
“Vascular
1,968
1,307
1,226”
Tariffs / trade policy
Demand Driver
New 2025 US tariffs and retaliatory measures expected to raise product costs and adversely affect demand and supply chains.
Relevance 65·Dependency 50·Confidence 90
Source evidence
“Tariffs are
expected to continue to result in an increase in certain product costs or have adverse impacts on, among other things, demand
for our products and supply chains.”
Multi-jurisdiction tax positions and in-process audits; changes in tax legislation and earnings repatriation could affect effective tax rate.
Relevance 65·Dependency 45·Confidence 90
Source evidence
“certain changes or future events, such as changes in tax legislation, geographic mix of earnings, completion of tax audits or earnings
repatriation plans, could have an impact on those estimates and our effective tax rate.”
EU GDPR
Regulatory Exposure
GDPR non-compliance penalties can reach 4% of total company revenue; privacy/AI regulatory compliance costs are increasing.
Relevance 60·Dependency 55·Confidence 95
Source evidence
“Non-compliance with the GDPR may result in monetary penalties of up to 4% of total company revenue.”
Spinal Implants
Revenue Exposure
Spinal Implants sales declined to $185M in 2025 from $707M in 2024, now a de minimis share (~0.7%) of total net sales.
Relevance 55·Dependency 100·Confidence 85
Source evidence
“Spinal Implants
185
707
713”
Certain single-sourced raw materials
Supplier Dependency
Certain raw materials are currently sourced from single suppliers, a supply-chain dependency despite generally multiple sources.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“however, certain of our raw
materials are currently sourced from single suppliers.”
AI-assisted virtual care platform technology
Technology Dependency
The Medical product line includes clinical communication and artificial intelligence-assisted virtual care platform technology, an AI-linked product exposure.
Relevance 55·Dependency 20·Confidence 80
Source evidence
“clinical communication and artificial intelligence-
assisted virtual care platform technology (Medical)”